Document:

Exhibit

Exhibit 10.1

RESIGNATION AGREEMENT

This Resignation Agreement ("Agreement") is made by and between Michael Perone ("Executive") and Barracuda Networks, Inc. (the "Company") (collectively referred to as the "Parties" or individually referred to as a "Party").

RECITALS

WHEREAS, Executive and Company entered into an employment offer letter dated July 24, 2013 (the "Offer Letter"); and

WHEREAS, Executive intends to voluntarily resign as Chief Marketing Officer ("CMO") effective June 30, 2017, and as an employee of the Company (the "Resignation") effective as of July 31, 2017 (the "Resignation Date"); and

WHEREAS, Executive and the Company both wish to ensure an orderly transition of Executive’s duties and responsibilities as CMO and continue his role as a member of the Company’s Board of Directors (the "Board") for the term of his election.

NOW, THEREFORE, in consideration of the mutual promises made herein, the Company and Executive hereby agree as follows:

COVENANTS
1.    Consideration.

		
	(a)
	Executive’s Employment Resignation. In connection with Executive’s Resignation, Executive agrees to execute any documentation deemed reasonably necessary by the Company to confirm Executive’s Resignation  as an officer of the Company and its subsidiaries and as an employee.

		
	(b)
	Continued Employment; Transition Services. Subject to the terms of this paragraph, the Company agrees to continue to employ Executive until the Resignation Date. During the period in which Executive is a Company employee, Executive will continue to receive his benefits and compensation in accordance with the current terms of an annualized base salary of $250,000 but without eligibility for a bonus payment and remain subject to his obligations under prior agreements with the Company (including applicable Company policies).  Executive will remain CMO until June 30, 2017. Should Executive’s employment be terminated by the Company prior to the Resignation Date, Executive will be entitled to the severance benefits described in clause (c) below if the termination is a Qualifying Termination (as defined below).

-1-

		
	(c)
	Severance.  Executive shall be entitled to the following on the earlier of: (A) a Qualifying Termination or (B) the Resignation Date (such date, the "Severance Date"):

(i)  Equity Awards and Equity Acceleration. The vesting of Executive’s then-outstanding Company stock options and restricted stock unit awards (collectively, the "Equity Awards") will accelerate in full such that all of the shares subject to such Equity Awards will become fully vested, settled, and exercisable, as applicable, as of the Severance Date.  Except as otherwise set forth in this Agreement, the Equity Awards shall continue to be governed by the terms and conditions of the applicable award agreement and the Company’s equity plan under which the award was granted, including that Executive may continue to satisfy the tax withholding obligations with respect to such Equity Awards in accordance with such agreements and plan.

(ii)  Cash Payment.  Executive will be entitled to receive a cash payment equal to $550,000.  Such amount will be paid, less any applicable withholding, within thirty (30) days of the Resignation Date. 

(iii) Continuation of Medical Coverage. Executive is entitled to receive continuing payments of the premiums required under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended ("COBRA") for a period of up to twelve (12) months following the termination of employment with the Company, if you and/or your covered dependents elect to continue the group health insurance coverage under the Company’s group health insurance plan. 

		
	(d)
	Definition of Qualifying Termination. A Qualifying Termination shall occur if prior to the Resignation Date, Executive’s employment with the Company is terminated by the Company other than for Cause (as defined in the Offer Letter).

2.    Impact on Other Arrangements. Executive understands and agrees that except as expressly provided for in this Agreement or as otherwise required by applicable law, Executive shall not be entitled to any other consideration or separation benefits.  

		
	(a)
	Board Relationship. Executive shall not receive any payment or benefit as a non-employee member of the Board under the Company’s Outside Director Compensation Policy ("Policy") until after the end of the Consulting Period (as defined below), after which time Executive shall be entitled to annual compensation for his service on the Board as set forth in the Policy.  Executive shall continue to have access to Company information and other access commensurate to that provided to outside directors, provided that Company shall provide additional access to Executive to the extent reasonably necessary to enable him to perform his consulting responsibilities to the Company.    

		
	(b)
	Consulting Services.  Executive will remain available to Company to assist with strategic technology development activities for twelve months following the 

-2-

Resignation Date ("Consulting Period"). Executive will be compensated during the Consulting Period in the amount of One Hundred Seventy Five Dollars ($175,000) per quarter, with such amounts payable on October 30, 2017, January 31, 2018, April 30, 2018, and July 31, 2018.

3.    Release of Claims.  In exchange for the consideration provided under this Agreement, Executive agrees to release any and all claims arising against the Company or any of its respective directors, officers, or current and former employees as of the date of the execution of this Agreement (collectively the "Releasees") including, but not limited to, the following: (a) claims arising under the federal constitution; (b) claims arising under the federal or any state statute, including the Age Discrimination in Employment Act of 1967 and the Older Workers Benefit Protection Act; (c) claims arising under federal, state or local laws prohibiting discrimination in employment; (d) claims for wrongful termination, breach of contract, breach of public policy, physical or mental harm or distress; (e) any claim for attorneys’ fees and costs; (f) any and all claims relating to, or arising from, Executive’s right to purchase, or actual purchase of shares of stock of the Company; (g) any unknown claims which, if known by the releaser at the time of the release must have materially affected Executive’s settlement with the Company, as provided for by California Civil Code Section 1542; and (h) any and all other claims arising from Executive’s employment relationship with the Company or the termination of that relationship.  Executive agrees that he will not file any legal action asserting any such claims.  Executive agrees that the release set forth in this section shall be and remain in effect in all respects as a complete general release as to the matters released.  This release does not extend to: (i) any obligations incurred under this Agreement; (ii) claims that cannot be released as a matter of law; (iii) any claims for indemnification under any agreement between Executive and the Company or under the Company’s bylaws or by law, and (iv) any claims for coverage under any D&O or similar insurance policy. 

4.    Tax Consequences. Executive agrees and understands that he is responsible for payment of all taxes on the payments and any other consideration provided hereunder by the Company and any penalties or assessments thereon. Payments under this Agreement are intended to either be exempt from or comply with the requirements of Section 409A of the Code and the final treasury regulations and official guidance thereunder (collectively, as each may be amended from time to time, "Section 409A") so that none of the payments and benefits to be provided hereunder will be subject to any additional tax imposed under Section 409A, and any ambiguities or ambiguous terms herein will be interpreted to so comply or to otherwise be exempt from Section 409A. 

5.     Trade Secrets and Confidential Information/Company Policies. Executive reaffirms and agrees to observe and abide by the terms of his Proprietary Information Agreement (the "Confidentiality Agreement"), specifically including the provisions therein regarding nondisclosure of the Company’s trade secrets and confidential and proprietary information. Executive acknowledges and agrees to continue to abide by the terms and conditions of the Company’s Insider Trading Policy any other Company policies or agreements otherwise 

-3-

pertaining to Executive in his position as executive officer and/or director of the Company and its subsidiaries (collectively, the "Company Policies") in accordance with their terms.

6.     Arbitration. Executive acknowledges and agrees that any and all controversies, claims, or disputes arising out of, relating to, or resulting from Executive’s employment to the Company or under this Agreement, shall be subject to arbitration in Santa Clara County, California in accordance with the provisions of the Confidentiality Agreement.  In the event any legal action is taken to enforce or interpret the terms of this Agreement, the prevailing party in such action shall be entitled to recover its legal fees and costs in addition to any other relief awarded. 

7.     Protected Activity Not Prohibited. Executive understands that nothing in this Agreement will in any way limit or prohibit Executive from engaging for a lawful purpose in any Protected Activity. For purposes of this Agreement, "Protected Activity" will mean filing a charge or complaint, or otherwise communicating, cooperating, or participating with, any state, federal, or other governmental agency, including the Securities and Exchange Commission, and the National Labor Relations Board with the understanding that Executive cannot recover any monetary relief for any such claims, unless such a waiver is prohibited by law. Notwithstanding any restrictions set forth in this Agreement, Executive understands that Executive is not required to obtain authorization from the Company prior to disclosing information to, or communicating with, such agencies, nor is Executive obligated to advise the Company as to any such disclosures or communications. Notwithstanding, in making any such disclosures or communications, Executive agrees to take all reasonable precautions to prevent any unauthorized use or disclosure of any information that may constitute Company confidential information under the Confidentiality Agreement to any parties other than the relevant government agencies. Executive further understands that "Protected Activity" does not include the disclosure of any Company attorney-client privileged communications, and that any such disclosure without the Company’s written consent shall constitute a material breach of this Agreement.

8.     Entire Agreement; Amendment. This Agreement represents the entire agreement and understanding between the Company and Executive concerning the subject matter of this Agreement and Executive’s resignation of employment with the Company and the events leading thereto and associated therewith, and supersedes and replaces any and all prior agreements and understandings concerning the subject matter of this Agreement and Executive’s employment relationship with the Company, with the exception of the Confidentiality Agreement, the equity plans and equity awards agreements under which the Equity Awards are granted, in each case as modified herein, and the Company Policies. For the sake of clarity, Executive specifically acknowledges that the Offer Letter’s provisions with respect to receipt of any severance payments or benefits in the event of his termination without cause or otherwise are expressly superseded by this Agreement and that the Executive shall receive no severance compensation of any sort under the Offer Letter. This Agreement may only be amended in a writing signed by Executive and the Company’s Chief Executive Officer. 

-4-

9.     Governing Law. This Agreement shall be governed by the laws of the State of California, without regard for choice-of-law provisions.  Executive consents to personal and exclusive jurisdiction and venue in the State of California. 

10.    Effective Date. This Agreement will become effective on the date it has been signed by both Parties (the "Effective Date"). Employee understands that this Agreement shall be null and void if not executed by him within 21 days. Each Party has 7 days after that Party signs this Agreement to revoke it. This Agreement will become effective on the 8th day after Employee signed this Agreement, so long as it has been signed by both Parties and has not been revoked by either Party before that date (the "Effective Date").

11.    Voluntary Execution of Agreement. Executive understands and agrees that he executed this Agreement voluntarily, and without any duress or undue influence on the part or behalf of the Company or any third party. Executive acknowledges that: (a) he has read this Agreement; (b) he has been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of his own choice or has elected not to retain legal counsel; (c) he understands the terms and consequences of this Agreement; (d) he is fully aware of the legal and binding effect of this Agreement; and (e) he has had 21 days within which to consider this Agreement and if signed prior to the end of such 21 day period that he has chosen to waive the remainder of such period.

IN WITNESS WHEREOF, the Parties have executed this Agreement on the respective dates set forth below.
	
			
	 

	 
	 
	 

	 
	 
	MICHAEL PERONE, an individual

	 
	 
	 

	Dated: June 29, 2017
	 
	/s/ Michael Perone

	 
	 
	Michael Perone

	 
	 
	 

	 

	 
	 
	 

	 
	 
	Barracuda Networks, Inc.

	 
	 
	 

	Dated: June 29, 2017
	 
	/s/ William BJ Jenkins

	 
	 
	William BJ Jenkins

	 
	 
	Chief Executive Officer

-5-EX-10.1

 Exhibit 10.1 

FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT 

This First Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of June 30, 2017, by and among
WESTERN ALLIANCE BANK, an Arizona corporation, with an office located at 55 Almaden Boulevard, Suite 100, San Jose, California 95113 (“Bank”), as collateral agent (in such capacity, the “Collateral Agent”), the Lenders listed on
Schedule 1.1 of the Agreement (as defined below) or otherwise a party hereto from time to time, including Bank in its capacity as a Lender, and SOLAR CAPITAL LTD., a Maryland corporation, with an office located at 500 Park Avenue, 3rd Floor,
New York, New York 10022 (“Solar;” together with Bank, each a “Lender” and collectively, the “Lenders”), and SUNESIS PHARMACEUTICALS, INC., a Delaware corporation with offices located at 395 Oyster Point Boulevard,
Suite 400, South San Francisco, California 94080 (“Borrower”). 
 RECITALS 

Borrower and Lenders are parties to that certain Loan and Security Agreement dated as of March 31, 2016 (as amended from time to time,
the “Agreement”). The parties desire to amend the Agreement in accordance with the terms of this Amendment. 
 NOW, THEREFORE, the parties agree
as follows: 
 1. The following defined terms in Section 1.1 of the Agreement hereby are added or amended and restated in their
entirety, as appropriate, to read as follows: 
 “Amortization Date” is January 1, 2018; provided that
if the Extended Interest-Only Period occurs, the Amortization Date shall be July 1, 2018. 
 “Extended
Interest-Only Period” means Borrower’s written election to Collateral Agent by December 31, 2017, to extend the Amortization Date to July 1, 2018, which election is contingent upon Borrower receiving at least Fifteen Million
Dollars ($15,000,000) in New Equity any time on or after June 1, 2017, but on or prior to December 31, 2017. 

“First Amendment” means that certain First Amendment to Loan and Security Agreement entered into as of the
First Amendment Effective Date by and among Collateral Agent, the Lenders and Borrower. 
 “First Amendment Effective
Date” means June 30, 2017. 
 “New Equity” means unrestricted (including not subject to any
clawback, redemption, escrow or similar contractual restriction, but excluding any restrictions in favor of the Lenders pursuant to this Agreement) cash proceeds received after June 1, 2017 from the issuance by Borrower of new equity securities
(in a private placement, public offering, at-the-market (ATM) offering or a combination thereof) on terms and conditions acceptable to Collateral Agent and the Lenders in their reasonable discretion. 

2. Sections 2.2(a) and 2.2(b) of the Agreement hereby are amended and restated in their entirety to read as follows: 

“(a) Availability. Lenders have made Term Loans to Borrower under this Agreement according to each Lender’s
Term Loan Commitment as set forth on Schedule 1.1 hereto (such term loans are hereinafter referred to singly as a “Term Loan”, and 

  
 -1- 

 
collectively as the “Term Loans”). As of the First Amendment Effective Date, immediately before giving effect to the First Amendment, the aggregate outstanding principal balance
of the Term Loans is Fourteen Million One Hundred Sixty-Six Thousand Six Hundred Sixty-Six and 67/100 Dollars ($14,166,666.67). After repayment, no Term Loan may be re-borrowed. 

(b) Repayment. 

(i) On the First Amendment Effective Date, Borrower shall repay Six Million Six Hundred Sixty-Six Thousand Six Hundred
Sixty-Six and 68/100 Dollars ($6,666,666.68) of the outstanding Term Loans (such that the outstanding principal balance of the Term Loans is Seven Million Five Hundred Thousand Dollars ($7,500,000)) along with the accrued portion of the Final
Payment with respect thereto in the amount of One Hundred Fifteen Thousand Three Hundred Seventy-Five and 94/100 Dollars ($115,375.94). Lenders hereby agree to waive the portion of the Prepayment Fee and the un-accrued portion of the Final Payment
with respect to such portion of the Term Loans so prepaid as of the First Amendment Effective Date provided that the balance of the Final Payment (i.e., $312,500.00 as of the First Amendment Effective Date) and Prepayment Fee (if applicable)
shall continue to be payable pursuant to the terms hereof. 
 (ii) Thereafter, Borrower shall make monthly payments of
interest on each Payment Date, through and including the Payment Date immediately preceding the Amortization Date. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive
equal monthly payments of principal, together with interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such Lender’s Term
Loans, (2) the effective rate of interest, as determined in Section 2.3(a), and (3) a repayment schedule equal to (a) twenty-eight (28) months, if the Amortization Date is January 1, 2018, or (b) twenty-two
(22) months, if the Amortization Date is July 1, 2018. All unpaid principal and accrued and unpaid interest with respect to the Term Loans are due and payable in full on the Maturity Date. Except as set forth in subsection 2.2(b)(i) above,
the Term Loans may only be prepaid in accordance with Sections 2.2(c) and 2.2(d).” 
 3. The first sentence of Section 6.6(a) of
the Agreement hereby is amended and restated in its entirety to read as follows: 
 “Maintain Borrower’s, and each
of Borrower’s domestic Subsidiaries’, primary Collateral Accounts with Bank or Bank’s Affiliates, and not less than twenty percent (20.00%) of Borrower’s and its’ Subsidiaries’ total deposits and investments with
Bank or Bank’s Affiliates.” 
 4. Exhibit C to the Agreement is hereby replaced with Exhibit C attached
hereto. 
 5. No course of dealing on the part of Bank or its officers, nor any failure or delay in the exercise of any right by Bank, shall
operate as a waiver thereof, and any single or partial exercise of any such right shall not preclude any later exercise of any such right. Bank’s failure at any time to require strict performance by Borrower of any provision shall not affect
any right of Bank thereafter to demand strict compliance and performance. Any suspension or waiver of a right must be in writing signed by an officer of Bank. 

  
 -2- 

 6. Unless otherwise defined, all initially capitalized terms in this Amendment shall be as
defined in the Agreement. The Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its respective terms and hereby is ratified and confirmed in all respects. Except as expressly set forth herein, the
execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Bank under the Agreement, as in effect prior to the date hereof. 

7. Borrower represents and warrants that the Representations and Warranties contained in the Agreement are true and correct in all respects as
of the date of this Amendment (except for the representations and warranties that speak as of a specific date, which shall be true and correct in all material respects), and that no Event of Default has occurred and is continuing. 

8. As a condition to the effectiveness of this Amendment, Bank shall have received, in form and substance satisfactory to Bank, the following:

 (a) this Amendment, duly executed by Borrower; 

(b) a Certificate of the Secretary of Borrower with respect to incumbency and resolutions authorizing the execution and
delivery of this Amendment; 
 (c) payment of the amounts of the Term Loan and Final Payment required pursuant to
Section 2.2(b)(i) of the Agreement (as amended hereby); 
 (d) all reasonable and documented Lenders’ Expenses
incurred through the date of this Amendment, which may be debited from any of Borrower’s accounts; and 
 (e) such other
documents, and completion of such other matters, as Bank may reasonably deem necessary or appropriate. 
 9. This Amendment may be executed
in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument. 

[Balance of Page Intentionally Left Blank] 

  
 -3- 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above
written. 
  

			
	BORROWER:
	
	SUNESIS PHARMACEUTICALS, INC.
		
	By:	 	/s/ Daniel N. Swisher, Jr.
	Name:	 	Daniel N. Swisher, Jr.
	Title:	 	CEO and President

  

			
	COLLATERAL AGENT AND LENDER:
	
	WESTERN ALLIANCE BANK
		
	By:	 	/s/ Bill Wickline
	Name:	 	Bill Wickline
	Title:	 	VP, Director of Portfolio Management

  

			
	LENDER:
	
	SOLAR CAPITAL LTD.
		
	By:	 	/s/ Anthony J. Storind
	Name:	 	Anthony J. Storind
	Title:	 	Authorized Signatory

 [Signature Page to First Amendment to Loan and Security Agreement] 

 CORPORATE BORROWING CERTIFICATE 

 

							
	BORROWER:	  	SUNESIS PHARMACEUTICALS, INC.	  	 	DATE: June 30, 2017	 
	LENDERS	  	 WESTERN ALLIANCE BANK, as Collateral Agent and Lender

SOLAR CAPITAL LTD., as Lender
	  			

 I hereby certify as follows, as of the date set forth above: 

1. I am the Secretary, Assistant Secretary or other officer of Borrower. My title is as set forth below. 

2. Borrower’s exact legal name is set forth above. Borrower is a corporation existing under the laws of the State of Delaware. 

3. Attached hereto as Exhibit A and Exhibit B, respectively, are true, correct and complete copies of (i) Borrower’s
Certificate of Incorporation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above; and (ii) Borrower’s Bylaws. Neither such Certificate of
Incorporation nor such Bylaws have been amended, annulled, rescinded, revoked or supplemented, and such Certificate of Incorporation and such Bylaws remain in full force and effect as of the date hereof. 

4. The following resolutions were duly and validly adopted by Borrower’s Board of Directors at a duly held meeting of such directors (or pursuant to a
unanimous written consent or other authorized corporate action). Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and Lenders may rely on them until
each Lender receives written notice of revocation from Borrower. 
 RESOLVED, that any one of
the following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower: 
  

											
	 Name
	 	Title	 	 	Signature	 	 	Authorized to
Add or Remove
Signatories
	  
 Daniel N. Swisher, Jr.
	 	  
  
	  
 President & CEO
	  
  
	 	  
  
	  

/s/ Daniel N. Swisher, Jr.
	  
  
	 	☒
	  
	 	  
	  
	 	 	  
	  
	 	 	☐

 RESOLVED FURTHER, that any one of the persons designated above
with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower. 

RESOLVED FURTHER, that such individuals may, on behalf of Borrower: 

    Borrow Money. Borrow money from Lenders. 

    Execute Loan Documents. Execute any loan documents any Lender requires. 

    Grant Security. Grant Collateral Agent and Lenders a security interest in any of Borrower’s assets. 

    Negotiate Items. Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in
which     Borrower has an interest and receive cash or otherwise use the proceeds. 
     Issue
Warrants. Issue warrants for Borrower’s capital stock. 
     Further Acts. Designate other individuals
to request advances, pay fees and costs and execute other documents or     agreements (including documents or agreement that waive Borrower’s right to a jury trial) they believe to be necessary to
    effectuate such resolutions. 

  
 5 

 RESOLVED FURTHER, that all acts authorized by the above
resolutions and any prior acts relating thereto are ratified. 
 5. The persons listed above are Borrower’s officers or employees with their titles and
signatures shown next to their names. 
  

			
	SUNESIS PHARMACEUTICALS, INC.
		
	By:	 	/s/ Daniel N. Swisher, Jr.
	  
 Name:
	 	 Daniel N. Swisher, Jr.

	  
 Title:
	 	 CEO and President

 *** If the Secretary, Assistant Secretary or other certifying officer executing above is
designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower. 

 

	
	 I, the
                                 of Borrower, hereby certify as to paragraphs 1
through 5 above, as of the date set forth above.

	
                [print
title]

  

			
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

  
 6 

 EXHIBIT C 

Compliance Certificate 
  

			
	 TO:
	  	
                   
     WESTERN ALLIANCE BANK, as Collateral Agent and Lender

                   
     SOLAR CAPITAL LTD., as Lender

		
	 FROM:
	  	
                   
     SUNESIS PHARMACEUTICALS, INC.

 1    The undersigned authorized officer (“Officer”) of SUNESIS PHARMACEUTICALS,
INC. (“Borrower”), hereby certifies that in accordance with the terms and conditions of the Loan and Security Agreement by and among Borrower, Collateral Agent, and the Lenders (the “Agreement”), 

2    (i) Borrower is in complete compliance for the period ending
                         with all required covenants except as noted below; 

3    (ii) There are no Events of Default, except as noted below; 

4    (iii) Except as noted below, all representations and warranties of Borrower stated in the Loan Documents are true and correct
in all material respects on this date except as noted below; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof;
and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date. 

5    (iv) Borrower, and each of Borrower’s Subsidiaries, have timely filed all required tax returns and reports, Borrower, and
each of Borrower’s Subsidiaries, has timely paid all foreign, federal, state, and local taxes, assessments, deposits and contributions owed by Borrower, or Subsidiary, except as otherwise permitted pursuant to the terms of Section 5.8 of
the Agreement; 
 6    (v) No Liens have been levied or claims made against Borrower or any of Borrower’s Subsidiaries
relating to unpaid employee payroll or benefits of which Borrower has not previously provided written notification to Collateral Agent and the Lenders. 

7    Attached are the required documents, if any, supporting our certification(s). The Officer, on behalf of Borrower, further
certifies that the attached financial statements are prepared in accordance with Generally Accepted Accounting Principles (GAAP) and are consistently applied from one period to the next except as explained in an accompanying letter or footnotes and
except, in the case of unaudited financial statements, for the absence of footnotes and subject to year-end audit adjustments as to the interim financial statements. Capitalized terms used but not otherwise defined herein shall have the meanings
given them in the Agreement. 
 8    Please indicate compliance status since the last Compliance Certificate by circling Yes, No, or
N/A under “Complies” column. 
  

															
	 Reporting Covenant
	  	 Requirement
	 	  	Complies
	 1)
	  	(A) Balance sheet and income statement	  	Monthly within 30 days	  				  	Yes	  	No	  	N/A
		  	(B) Cash flow statement	  	Quarterly within 30 days	  				  	Yes	  	No	  	N/A

																	
	 2)
	  	Annual (CPA Audited) statements	  	Within 180 days after Fiscal Year End	 		 	Yes	  	 	No	 	  	 	N/A	 
	 3)
	  	Annual Financial Projections/Budget (prepared on a monthly basis)	  	Annually (w/n 10 days of FYE). and when revised	 		 	Yes	  	 	No	 	  	 	N/A	 
	 4)
	  	A/R & A/P agings	  	If applicable	 		 	Yes	  	 	No	 	  	 	N/A	 
	 5)
	  	8-K, 10-K and 10-Q Filings	  	Within 5 days of filing	 		 	Yes	  	 	No	 	  	 	N/A	 
	 6)
	  	Compliance Certificate	  	Monthly within 30 days	 		 	Yes	  	 	No	 	  	 	N/A	 
	 7)
	  	IP Report	  	when required	 		 	Yes	  	 	No	 	  	 	N/A	 
	 8)
	  	Total amount of Borrower’s consolidated cash and cash equivalents at the last day of the measurement period	  		 	$                    	 		  				  			
	 9)
	  	Total amount of Borrower’s and domestic Subsidiaries’ cash and cash equivalents maintained with Bank or Bank’s affiliates at the last day of the measurement period	  	At least 20% of (8)	 	$                    	 	Yes	  	 	No	 	  			
	 10)
	  	Total amount of Borrower’s consolidated cash and cash equivalents outside the U.S. at the last day of the measurement period	  	Not greater than 25% of (8)	 	$                    	 	Yes	  	 	No	 	  			
		  		  		 		 		  				  			
		  	Deposit and Securities Accounts	  	(Please list all accounts; attach separate sheet if additional space needed)	 
	 	  	 Bank
	  	 Account Number
	 	 New Account?
	  	Acct Control
Agmt in place?	 
							
	 1)
	  		  		 	Yes	 	No	  	 	Yes	 	  	 	No	 
							
	 2)
	  		  		 	Yes	 	No	  	 	Yes	 	  	 	No	 
							
	 3)
	  		  		 	Yes	 	No	  	 	Yes	 	  	 	No	 
							
	 4)
	  		  		 	Yes	 	No	  	 	Yes	 	  	 	No	 
							
	 5)
	  		  		 	Yes	 	No	  	 	Yes	 	  	 	No	 
							
	 6)
	  		  		 	Yes	 	No	  	 	Yes	 	  	 	No	 

									
	 Other Matters
	  				  			
			
	 Have there been any changes in senior management since the last Compliance Certificate?
	  	 	Yes	 	  	 	No	 
			
	 Have there been any transfers/sales/disposals/retirement of Collateral or IP prohibited by the
Agreement?
	  	 	Yes	 	  	 	No	 
			
	 Have there been any new or pending claims or causes of action against Borrower that involve more
than $250,000?
	  	 	Yes	 	  	 	No	 

  

																			
	 Exceptions
	  		  				  				  				  			
	 Please explain any exceptions with respect to the certification above: (If
no exceptions exist, state “No exceptions.” Attach separate sheet if additional

space needed.)
	  	 	 	 
	  				  				  				  			
	  	 	 	 
	  				  				  				  			
	  	 	 	 
	  				  				  				  			
	  	 	 	 

 

							
				
	SUNESIS	 		 		 	 
	PHARMACEUTICALS, INC.	 		 		 	    DATE
	By:	 		 		 	
				
	Name:	 		 		 	
	Title:	 		 		 	

 

 
							
	
	LENDERS USE
 ONLY

				
	Received by:	  	  
	  	Verified by:	  	  

				
	Date:	  		  	Date:	  	
				
		  	  
	  		  	  

				
	Compliance Status	  		  	Yes	  	No

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]